Psoriasis vulgaris is a chronic, inflammatory skin disease characterized by a dysregulated immune response and it is associated with substantial systemic comorbidities. Biological drugs such as tumour necrosis factor (TNF)‐α… Click to show full abstract
Psoriasis vulgaris is a chronic, inflammatory skin disease characterized by a dysregulated immune response and it is associated with substantial systemic comorbidities. Biological drugs such as tumour necrosis factor (TNF)‐α inhibitors can ameliorate the disease but are expensive. Biosimilar drugs have the same amino‐acid sequence as the originator, but differences in manufacturing can affect biological activity, efficacy and tolerability.
               
Click one of the above tabs to view related content.